Publication | Open Access

Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety

MedicineCancer ManagementGynecologyGermline Brca1/2 MutationCancer TreatmentOncologyRadiation OncologyGynecology OncologyOlaparib MonotherapyEndocrine-related CancerOvarian CancerResponse Rates